Anika Therapeutics amends Bank of America revolving credit facility, extends maturity to 2031
PUBT·- Anika Therapeutics amended its revolving credit agreement with Bank of America on July 10, 2026, maintaining a USD 50 million line of credit extended to July 10, 2031. - The agreement includes an accordion feature allowing for up to an additional USD 50 million, with borrowings priced based on SOFR plus rates of 0.25% to 1.25%. - Lenders retain a first-priority lien on most assets, and financial covenants limit leverage and interest coverage ratios.